Science Group reports record profit on corporate investment gain By Investing.com

Adjusted operating profit rose to £23.1m (from £21.5m) and adjusted basic EPS increased to 40.2p (from 36.2p), while revenue was broadly flat at £111.7m. Statutory PBT jumped to £41.5m, driven by a £24.1m pre-tax gain after selling a c.21.8% stake in Ricardo (acquired for £32.7m and sold at 430p, >70% ROI); statutory basic EPS rose to 75.1p. Balance sheet and shareholder returns strengthened: cash generated from operations £31.8m, year-end cash £72.6m (net funds £61.2m), 1.996m shares repurchased for £10.7m (avg 538p), final dividend raised 25% to 10.0p, and new banking facilities secured (£12.0m term loans and £30.0m RCF).

Analysis

Management’s recent capital allocation moves reveal an active, opportunistic playbook that materially changes the investment identity of the company — from steady engineering services provider to a player that harvests short-duration, high-return stakes alongside organic operations. That optionality is asymmetric: disciplined crystallisations of minority stakes can create step-changes in reported profitability and cash without altering core margins, which supports a re-rating if management repeats or scales the playbook prudently.

Operationally, the business is a two-speed machine where service contracts provide recurring cash while systems work is lumpy and capex-sensitive; this split magnifies cyclicality, so macro indicators of industrial R&D and manufacturing capex flow directly into near-term orderbooks. The recently renewed banking maturity profile reduces refinancing tail risk and creates room for bolt-on M&A, but it also raises the bar on deployment choices — poor deals would quickly compress return-on-capital versus returning cash to shareholders.

Near-term catalysts to monitor are fresh contract awards, any repeat minority-stake activity, and upcoming trading updates that will reveal whether order momentum is real or a post-event spike. Key tail risks: a sharp pullback in industrial R&D budgets, a failed large acquisition, or dependence on one-off strategic disposals to meet profit expectations. Time-horizons: days for trading volatility around releases, months for deal cadence to prove repeatability, and 12–24 months for structural re-rating if capital allocation consistently adds shareholder value.

Key Decisions for Investors

• Long SAG.L equity (size 2–4% of portfolio). Timeframe 6–12 months. Rationale: asymmetric upside from repeatable stake crystallisations plus steady cash generation; target 30–40% upside, place defensive stop-loss at -12% to limit downside if industrial orders reverse.
• Buy a 12–18 month call spread on SAG.L to capture upside while capping premium (buy near-the-money call, sell a higher strike ~30–40% out). Timeframe 12–18 months. Risk/reward: limited downside (premium paid) with 3–4x potential on-basis if re-rating occurs following another successful stake realisation or meaningful margin expansion.
• Pair trade: long SAG.L / short RCDO.L (ratio ~1:0.6) to express idiosyncratic capital-allocation call while hedging sector cyclicality. Timeframe 9–12 months. Target relative outperformance 20–30%; unwind on divergence >30% against position or on confirmation of sector-wide capex collapse.
• Event hedge: if the company announces a new minority stake purchase, buy protection (put) expiring just after the announcement window to cover execution/financing risk. Timeframe days–weeks around announcement. Treat premium as insurance against a deal that dilutes returns or fails to crystallise value.